- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06252870
Studie som testar två konditioneringsregimer med en enda profylax av GVHD med cyklofosfamid och metotrexat efter transplantation hos patienter som är kvalificerade för allografttransplantation med matchad donator (CY-MET-RIC)
Randomiserad fas 2-studie som testar två konditioneringsregimer med en enda profylax av graft-versus-host-sjukdom med cyklofosfamid och metotrexat efter transplantation hos patienter som är kvalificerade för allografttransplantation med matchad donator
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH).
Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA donors, the use of cyclophosphamide (CY) administered in high doses at early post-transplant (PT) (=PTCY) (Days +3 and +4 or +5) has shown excellent control of acute and chronic GVH, even enabling the discontinuation of other immunosuppressive drugs administered after allo-CSH (ciclosporin, mycophenolate mofetyl (MMF) or Cellcept).
This step has already been taken in the context of allo-CSH with myeloablative conditioning (MAC), which is a minoritary conditioning in adults.
However, in the context of allo-CSH with reduced-intensity conditioning (RIC), which predominates in adults, this strategy seems insufficient to prevent the risk of GVHD.
The idea of reducing the use of immunosuppressants in the context of RIC/HLA-compatible transplants seems, however, still relevant, in order to reduce their adverse effects, improve patients' quality of life and enhance the reconstitution of the post-transplant immune system.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Läkemedel: Methotrexate
- Läkemedel: Post-Transplant Cyclophosphamide
- Läkemedel: Fludarabine
- Läkemedel: Cycophosphamide
- Läkemedel: Anti-Thymoglobulin
- Strålning: total body irradiation
- Övrig: hematopoietic stem cells
- Övrig: Graft nuclear cells
- Övrig: Donor Lymphocytes Injection
- Läkemedel: Clofarabine
- Läkemedel: Fludarabine
- Läkemedel: Thiotepa
- Läkemedel: Busulfan
Detaljerad beskrivning
For this reason, the investigators now wish to test the administration of a combination of a high dose of early post-transplant CY (PTCY) and methotrexate (MTX) on days (D) D+1, D+4, D+6, D+11 (doses already performed in MAC transplant prophylaxis), with anti-lymphocyte serum (ALS) with RIC conditioning, without ciclosporin or MMF.
The investigators hypothesize that administration of this PTCY+MTX combination will enable immunosuppressive drugs to be discontinued as early as D+11 post-transplant, compared with the usual average of 3 to 4 months.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Amandine LE BOURGEOIS, MD
- Telefonnummer: +33 02 40 08 32 71
- E-post: amandine.lebourgeois@chu-nantes.fr
Studieorter
-
-
-
Angers, Frankrike
- Rekrytering
- CHU Angers
-
Kontakt:
- Sylvain THEPOT, MD
- Telefonnummer: +33 0241354482
- E-post: sylvain.thepot@chu-angers.fr
-
Brest, Frankrike
- Rekrytering
- CHU Brest
-
Kontakt:
- Marie-Anne COUTURIER, MD
- Telefonnummer: +33 0298223765
- E-post: marie-anne.couturier@chu-brest.fr
-
Nantes, Frankrike
- Rekrytering
- CHU Nantes
-
Kontakt:
- Amandine LE BOURGEOIS, MD
- Telefonnummer: +33 0240083271
- E-post: amandine.lebourgeois@chu-nantes.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age: ≥ 18 and ≤ 70 years old
- Patient with hematologic malignancy
- Indication for HSC allograft with attenuated conditioning
- Pluripotent stem cell (PSC) engraftment
- Availability of a 10/10 familial or non-familial HLA compatible donor
- Consent to the protocol
- ECOG <=2
- Woman of childbearing age with negative pregnancy test and on highly effective contraception during treatment and for a period of 12 months after stopping MTX and CY
- Man of childbearing age with highly effective contraception during treatment and for a period of 6 months after stopping MTX and CY and a period of 12 months after stopping MTX and CY if TBF conditioning regimen arm
- Negative Hepatitis B, C, HIV serologies
- Social security affiliation
Exclusion Criteria:
- History of allograft
- Patient eligible for myeloablative conditioning (MAC)
- Bone marrow transplant
- Other progressive cancerous disease, or antecedent of cancer in the last five years, with the exception of a carcinoma of the skin or a carcinoma in situ of the uterine cole treated and in remission.
- Progressive psychiatric condition
- Pregnant or breastfeeding woman,
- Woman or man of childbearing age with lack of effective contraception
- Serious and uncontrolled concomitant infection
- Cardiac: systolic ejection fraction < 50% by transthoracic ultrasound or by isotopic method (isotope gamma angiography), NYHA II, III or IV heart failure, active rhythmic, valvular or ischemic heart disease or anteriority
- Respiratory with EFR: DLCOc <40% of theoretical
- Renal: creatinine clearance < 50 ml/min (assessment with MDRD method)
- Urological: active urinary tract infection, history of acute urothelial toxicity due to cytotoxic chemotherapy or radiotherapy, known obstruction of urinary flow, pre-existing hemorrhagic cystitis
- Hepatic: transaminases greater than 5 times normal or bilirubin greater than 2 times normal
- Person protected by law (major under guardianship, curatorship or legal protection)
- Vaccination against yellow fever in the last year
- Known or suspected hypersensitivity to rabbit proteins as well as to the active substance and excipients of all investigational and ancillary drugs administered during the study,
- Contraindication to any of the investigational or adjuvant drugs administered during the study
- Patient not speaking French
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: (CLO)-BALTIMORE
BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY |
15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
Andra namn:
50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
Andra namn:
Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
Andra namn:
Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0) Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
Andra namn:
2 grays on Day-1 before graft (=Day0)
Andra namn:
High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
Andra namn:
Graft nuclear cells CD3+ cells if needed after transplantation DLI with CD3+ if relapse after transplantation or in prevention of relapse
Andra namn:
Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0) Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
Andra namn:
|
|
Aktiv komparator: TBF
Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY |
15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
Andra namn:
50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
Andra namn:
Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
Andra namn:
Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
Andra namn:
High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
Andra namn:
Graft nuclear cells CD3+ cells if needed after transplantation DLI with CD3+ if relapse after transplantation or in prevention of relapse
Andra namn:
Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
Andra namn:
Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0) Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of grade 3-4 acute GVHD following allo-CSH for all patients and for each conditioning group (Baltimore and TBF).
Tidsram: Post-transplant through study completion, an average of 1 year
|
Estimation of the incidence of grade 3 and 4 acute GVHD following allo-CSH (excluding post-DLI* acute GVHD) according to Mount Sinai criteria. |
Post-transplant through study completion, an average of 1 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of engraftment
Tidsram: Month 1 post-transplant
|
Engraftment assessed on hematological reconstitution (number of days of aplasia with PNN <0.5 G/L and platelets < 20 G/L, number of platelet and red cell concentrate transfusions) |
Month 1 post-transplant
|
|
Overall survival (OS)
Tidsram: Post-transplant through study completion, an average of 1 year
|
survival between day 0 of transplantation and date of death or last follow-up |
Post-transplant through study completion, an average of 1 year
|
|
Disease-free survival (DFS)
Tidsram: Post-transplant through study completion, an average of 1 year
|
survival between day 0 of transplantation and date of relapse, death or last follow-up |
Post-transplant through study completion, an average of 1 year
|
|
GVHD and relapse-free survival (GRFS)
Tidsram: Post-transplant through study completion, an average of 1 year
|
relapse-free survival without grade 3-4 acute GVHD or chronic GVHD requiring systemic treatment |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of acute GVHD grade 2-4
Tidsram: Post-transplant through study completion, an average of 1 year
|
Acute GVH grade 2-4 according to Mount Sinai criteria |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of chronic GVHD
Tidsram: From month 3 post-transplant through study completion, an average of 1 year
|
Chronic GVHD according to NCI criteria |
From month 3 post-transplant through study completion, an average of 1 year
|
|
Incidence of corticoresistant acute GVHD
Tidsram: Post-transplant through study completion, an average of 1 year
|
Acute corticoresistant GVHD according to the criteria of Mohty et al. defined by :
|
Post-transplant through study completion, an average of 1 year
|
|
Incidence of non-relapse mortality (NRM)
Tidsram: Post-transplant through study completion, an average of 1 year
|
any death unrelated to relapse or disease progression |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of relapse
Tidsram: Post-transplant through study completion, an average of 1 year
|
any documented disease recurrence |
Post-transplant through study completion, an average of 1 year
|
|
Chimerism
Tidsram: At Month1, Month2, Month3, Month6, Month12 post-transplant
|
Total donor or mixed chimerism. Total donor chimerism = result >95% donor CD3+ cells. Mixed chimerism = result >5% and <95% donor CD3+ cells. |
At Month1, Month2, Month3, Month6, Month12 post-transplant
|
|
Immune reconstitution
Tidsram: At Month3, Month6, Month9, Month12 post-transplant
|
T, NK, B lymphocytes and monocytes |
At Month3, Month6, Month9, Month12 post-transplant
|
|
Grade 3 and 4 post-transplant adverse events
Tidsram: Post-transplant through study completion, an average of 1 year
|
Grade 3 and 4 post-transplant adverse events (dates of occurrence) (NCI CTCAE criteria, version number 5) |
Post-transplant through study completion, an average of 1 year
|
|
Incidence of viral, bacteriological, fungal and parasitic infections
Tidsram: Post-transplant through study completion, an average of 1 year
|
Infections: viral (CMV, EBV, BKV, adenovirus), bacteriological, fungal and parasitic |
Post-transplant through study completion, an average of 1 year
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Marie-Anne COUTURIER, MD, University Hospital, Brest
- Huvudutredare: Sylvain THEPOT, MD, University Hospital, Angers
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Immunsystemets sjukdomar
- Hematologiska sjukdomar
- Hemiska och lymfsjukdomar
- Hematologiska neoplasmer
- Graft vs Host Disease
- Svavelföreningar
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Terapeutik
- Nukleinsyror, nukleotider och nukleosider
- Kolväten, acyklisk
- Kolväten
- Puriner
- Alkan
- Alkohol
- Butylenglykol
- Glykol
- Mesylater
- Alkanesulfonater
- Alkanesulfonsyror
- Sulfonsyror
- Svavelsyror
- Fosforamider
- Organofosforföreningar
- Nukleosider
- Pteriner
- Pteridiner
- Arabinonukleosider
- Aminopterin
- Strålbehandling
- Trietylenefosforamid
- Aziridiner
- Aziriner
- Ribonukleotider
- Nukleotid
- Adeninnukleotider
- Purintnukleotider
- Clofarabin
- Metotrexat
- Busulfan
- Thiotepa
- fludarabin
- Helkroppsbestrålning
Andra studie-ID-nummer
- RC23_0286
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .